entertainment -WSS

entertainment

author：leisure time 2025-09-27 12:35:49 - browse：5684

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Three trends to watch in biotech in 2024

leisure time

WSS

SEC charges former device maker CEO with $41 million fraud

Slain Parkland victim's father speaks out following reenactment

What STAT readers think about the FDA and patient advocacy

David Ricks of Eli Lilly: best biopharma CEO of 2023

Albert Bourla of Pfizer: worst biopharma CEO of 2023

How to keep neuroscience’s past racism from being its future

focus

entertainment

hotspot

Psychedelics group wrestles with new pharma identity

Parkland mass shooting to be reenacted for lawsuit

Bright Health sells Medicare Advantage business to Molina

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert

After affirmative action ruling, medical educators look to 'holistic review'

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Prosecutors seek bail revocation for FTX founder Sam Bankman

Peter Hotez and the public health issue of online harassment

Violet CEO on training clinicians to promote more inclusive care

knowledge

Can sheer will power keep patients alive in their dying hours?

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

California Joshua trees severely burned in massive wildfire

Pharma needs to include young adults in clinical research

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

explore

leisure time

hotspot

explore